BMO Capital Reiterates Biogen (BIIB) at Outperform, Eisai Sees More Value in lecanemab Than Aduhelm
Tweet Send to a Friend
BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $238.00 price target on Biogen (NASDAQ: BIIB), following restructuring ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
